ANDA 73143, held by Watson Laboratories. Cyclobenzaprine Hydrochloride.
As of Nov 21, 2026, ANDA 73143 (Cyclobenzaprine Hydrochloride), held by Watson Laboratories, was first approved by FDA on Nov 27, 1991, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 27, 1991 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cyclobenzaprine Hydrochloride10MG · tablet;oral | Cyclobenzaprine Hydrochloride | Discontinued |
| Nov 8, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Nov 7, 2002 | Supplement 6Manufacturing | Approved | None posted |
| Aug 23, 2002 | Supplement 5Manufacturing | Approved | None posted |
| Sep 5, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Nov 10, 1999 | Supplement 3Manufacturing | Approved | None posted |
| Oct 6, 1992 | Supplement 2Labeling | Approved | None posted |
| Sep 23, 1992 | Supplement 1Manufacturing | Approved | None posted |
| Nov 27, 1991 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters